MedTrace Logo

Cohort Study of the Clinical Course of Macular Diseases in Japanese

NCT02081339 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2016-09-23

No results posted yet for this study

Summary

Recent clinical introduction of anti-vascular endothelial growth factor agents may change the clinical course of macular diseases, including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation (RAP), central serous chorioretinopathy (CSC), myopic choroidal neovascularization (CNV), retinal vein occlusion (RVO), diabetic macular edema (DME), and so forth.

Patients with such macular diseases are registered and and are followed up for 5 years with appropriate treatment for each patient. By the analysis of the correlation between initial examinations and final visual acuity, factors associated with good visual prognosis will be elucidated.

Conditions

  • Macular Disease

Interventions

DRUG

ranibizumab, aflibercept, pegaptanib, verteporphin

Sponsors & Collaborators

  • Kyoto University, Graduate School of Medicine

    lead OTHER

Principal Investigators

  • Nagahisa Yoshimura, MD · Kyoto University, Graduate School of Medicine

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2022-03-31
Completion
2024-03-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02081339 on ClinicalTrials.gov